|
|
|
|
|
|
Sponsors and Collaborators: |
Cancer and Leukemia Group B National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00006486 |
RATIONALE: Carboxyamidotriazole may stop the growth of kidney cancer by stopping blood flow to the tumor.
PURPOSE: Randomized phase II trial to study the effectiveness of carboxyamidotriazole in treating patients who have metastatic kidney cancer.
Condition | Intervention | Phase |
Kidney Cancer |
Drug: carboxyamidotriazole |
Phase II |
MedlinePlus related topics: | Cancer Kidney Cancer |
ChemIDplus related topics: | L 651582 |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control |
Official Title: | A Phase II Randomized Discontinuation Trial Of Carboxyaminoimidazole (CAI, NSC 609974) In Metastatic Renal Carcinoma |
Study Start Date: | October 2000 |
OBJECTIVES:
OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified according to time from diagnosis of metastatic disease to study entry (fewer than 24 months vs 24 months or more).
Patients receive oral carboxyamidotriazole (CAI) daily for 4 weeks. Treatment repeats for 4 courses in the absence of disease progression or unacceptable toxicity.
After 4 courses, patients experiencing complete or partial response continue treatment until disease progression or unacceptable toxicity. Patients with stable disease are randomized to one of two treatment arms.
Patients are followed every 6 months.
PROJECTED ACCRUAL: A maximum of 335 patients will be accrued for this study within 15-25 months.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed renal cell carcinoma
At least 1 unidimensionally measurable lesion
The following lesions are not considered measurable:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Show 48 Study Locations |
Cancer and Leukemia Group B |
National Cancer Institute (NCI) |
Study Chair: | Walter M. Stadler, MD, FACP | University of Chicago |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 1;23(16):3726-32. Erratum in: J Clin Oncol. 2005 Jul 20;23(21):4808. Ratain, Mark J [added].
  |
Stadler WM, Rosner G, Rini B, et al.: Successful implementation of the randomized discontinuation trial design (RDTD) with the putative antiangiogenic agent carboxyaminoimidazole (CAI) in renal cell carcinoma (RCC). A Cancer and Leukemia Group B (CALGB) Study. [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-773, 2003.
  |
Study ID Numbers: | CDR0000068317, CLB-69901 |
First Received: | November 6, 2000 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00006486 |
Health Authority: | United States: Federal Government |
|
|
|
|
|